Lomustine
- Generic Name
- Lomustine
- Brand Names
- Ceenu, Gleostine
- Drug Type
- Small Molecule
- Chemical Formula
- C9H16ClN3O2
- CAS Number
- 13010-47-4
- Unique Ingredient Identifier
- 7BRF0Z81KG
- Background
An alkylating agent of value against both hematologic malignancies and solid tumors.
- Indication
For the treatment of primary and metastatic brain tumors as a component of combination chemotherapy in addition to appropriate surgical and/or radiotherapeutic procedures. Also used in combination with other agents as secondary therapy for the treatment of refractory or relapsed Hodgkin's disease.
- Associated Conditions
- Metastatic Brain Tumors, Primary Brain Neoplasm, Refractory Hodgkin Lymphoma
Methotrexate, Procarbazine, Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Primary CNS Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2003-12-11
- Last Posted Date
- 2017-04-21
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 1
- Registration Number
- NCT00074191
- Locations
- 🇺🇸
Oregon Health & Science University Cancer Institute, Portland, Oregon, United States
Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma
- Conditions
- Intraocular MelanomaMelanoma (Skin)
- First Posted Date
- 2003-11-06
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00072345
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Oral Combination Chemotherapy in Treating Elderly Patients With Intermediate or High-Grade Non-Hodgkin's Lymphomas
- Conditions
- Lymphoma
- First Posted Date
- 2003-09-24
- Last Posted Date
- 2011-01-17
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT00003113
- Locations
- 🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme
- Conditions
- Glioblastoma
- First Posted Date
- 2003-09-16
- Last Posted Date
- 2008-04-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 118
- Registration Number
- NCT00068952
- Locations
Pfizer Investigational Site
Combination Chemotherapy in Treating Patients With AIDS-Related Hodgkin's Disease
- Conditions
- Lymphoma
- First Posted Date
- 2003-08-13
- Last Posted Date
- 2010-06-11
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 5
- Registration Number
- NCT00003114
- Locations
- 🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Intrathecal Radioimmunotherapy, Radiation Therapy, and Chemotherapy After Surgery in Treating Patients With Medulloblastoma
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- Procedure: adjuvant therapyRadiation: iodine I 131 monoclonal antibody 3F8Radiation: radiation therapy
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2020-05-11
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT00058370
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States
Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- University of Leicester
- Target Recruit Count
- 316
- Registration Number
- NCT00053872
- Locations
- 🇫🇷
Institut Curie Hopital, Paris, France
🇩🇪Universitaets - Kinderklinik Wuerzburg, Wuerzburg, Germany
🇳🇱Academisch Medisch Centrum at University of Amsterdam, Amsterdam, Netherlands
Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- Radiation: radiation therapy
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2018-06-18
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 299
- Registration Number
- NCT00002569
- Locations
- 🇺🇸
Veterans Affairs Medical Center - West Los Angeles, Los Angeles, California, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸Louisiana State University Health Sciences Center - Shreveport, Shreveport, Louisiana, United States
Temozolomide Plus Lomustine Followed by Radiation Therapy in Treating Patients With High-Grade Malignant Glioma
- Conditions
- Brain TumorCentral Nervous System Tumor
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-02-13
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 32
- Registration Number
- NCT00006024
- Locations
- 🇺🇸
Children's Hospital of Columbus, Columbus, Ohio, United States
🇺🇸Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
🇨🇭Swiss Pediatric Oncology Group Lausanne, Lausanne, Switzerland
Low-Dose Radiation and Combination Chemotherapy Following Surgery in Children With Newly Diagnosed Medulloblastoma
- Conditions
- Brain TumorsCentral Nervous System TumorsMedulloblastoma
- Interventions
- Radiation: Craniospinal Radiation
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2019-04-25
- Lead Sponsor
- Children's Hospital of Philadelphia
- Target Recruit Count
- 30
- Registration Number
- NCT00031590
- Locations
- 🇺🇸
Lucile Packard Children's Hospital at Stanford University Medical Center, Palo Alto, California, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.